RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition

Henrietta Venter1*, Rumana Mowla1, Thelma Ohene-Agyei2 and Shutao Ma3

1 School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, SA, Australia, 2 Department of Pharmacology, University of Cambridge, Cambridge, UK, 3 Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan, China

Drug efflux protein complexes confer multidrug resistance on bacteria by transporting a wide spectrum of structurally diverse antibiotics. Moreover, organisms can only acquire resistance in the presence of an active efflux pump. The substrate range of drug efflux pumps is not limited to antibiotics, but it also includes toxins, dyes, detergents, lipids, and molecules involved in quorum sensing; hence efflux pumps are also associated with virulence and biofilm formation. Inhibitors of efflux pumps are therefore attractive compounds to reverse multidrug resistance and to prevent the development of resistance in clinically relevant bacterial pathogens. Recent successes on the structure determination and functional analysis of the AcrB and MexB components of the AcrAB-TolC and MexAB-OprM drug efflux systems as well as the structure of the fully assembled, functional triparted AcrAB-ToIC complex significantly contributed to our understanding of the mechanism of substrate transport and the options for inhibition of efflux. These data, combined with the well-developed methodologies for measuring efflux pump inhibition, could allow the rational design, and subsequent experimental verification of potential efflux pump inhibitors (EPIs). In this review we will explore how the available biochemical and structural information can be translated into the discovery and development of new compounds that could reverse drug resistance in Gram-negative pathogens. The current literature on EPIs will also be analyzed and the reasons why no compounds have yet progressed into clinical use will be explored.

Keywords: multidrug resistance, drug efflux, efflux pump inhibitor, Gram-negative, pathogen, antimicrobial resistance

Introduction

Over the last two decades there has been a dramatic surge in the number of multidrug resistant bacteria, yet paradoxically the number of pharmaceutical companies developing new antimicrobial agents has dwindled during this same period. As a result, antibiotic resistance is now one of the world’s most pressing health problems (WHO, 2014). Therefore, new treatments to combat drug resistant bacteria are urgently needed if we do not want to return to the high mortality rates associated with infections during the pre-antibiotic era (Bush et al., 2011; WHO, 2014).

Hospital acquired pathogens such as Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, and Pseudomonas aeruginosa which can cause life-threatening infections display high levels of antibiotic resistance (Poole, 2011; Bassetti et al., 2013). Resistance of K. pneumonia
Drug Efflux Pumps in Gram-Negative Bacteria

Gram-negative pathogens rely on tripartite protein assemblies that span their double membrane to pump antibiotics from the cell. The tripartite complex consists of an inner membrane protein (IMP) of the resistance nodulation cell division (RND) family, an outer-membrane protein (OMP), and a periplasmic membrane fusion protein (MFP) which connect the other two proteins (Figure 1). The inner-membrane protein catalyzes drug/H⁺ antiport and is the part of the complex responsible for drug selectivity. The best studied tripartite drug efflux complexes are the AcrA-AcrB-TolC and MexA-MexB-OprM transporters from *Escherichia coli* and *P. aeruginosa*, respectively, (Du et al., 2013). The IMPs AcrB and MexB share 86% similarity and MexB can functionally substitute for AcrB (Krishnamoorthy et al., 2008; Welch et al., 2010). The asymmetric structure of the AcrB homotrimer and subsequent biochemical analysis revealed a functional rotating mechanism where the monomers cycle through the different states loose (L), tight (T), and open (O; Murakami et al., 2006; Seeger et al., 2006, 2008b). IMPs such as AcrB consist of a transmembrane domain and periplasmic domain. The drug efflux pathway from the periplasm/outer membrane leaflet through the periplasmic domain of AcrB has been the focus of many studies and are now relatively well-understood (Murakami, 2008; Seeger et al., 2008a; Eicher et al., 2009; Misra and Bavro, 2009; Nikaido and Takatsuka, 2009; Pos, 2009; Nikaido, 2011; Nikaido and Pages, 2012; Ruggeroni et al., 2013a,b). Recently, it was also found that mutations at the cytoplasmic face of MexB affected transport of drugs with targets inside the cell (Ohene-Agyei et al., 2012). This raises the possibility that similar to the cytoplasmic pathway for Cu(II) in CusA (Delmar et al., 2014), MexB might also have the ability to remove antibiotics from the inner membrane leaflet/cytoplasm (Ohene-Agyei et al., 2012). Targeted geometric simulations showed that such a cytoplasmic pathway could be possible even though it would not necessarily out-compete the periplasmic channel for
drug binding and transport (Phillips and Gnanakaran, 2015). Biochemical and structural analysis revealed that the periplasmic binding site in AcrB contains a shallow (proximal) and deep (distal) binding pocket separated by a switch loop (G-loop) consisting of residues 614–621 (Nakashima et al., 2011; Eicher et al., 2012; Cha et al., 2014). Conformational flexibility in this loop is necessary to move the substrate along the extended binding site. Mutations that change the small glycine residues in this loop to bulkier residues affects transport of larger macrolide antibiotics such as erythromycin while the activity toward smaller compounds such as novobiocin, ethidium, and chloramphenicol remained unaffected (Bohnert et al., 2008; Wehmeier et al., 2009; Nakashima et al., 2011, 2013; Eicher et al., 2012). Therefore, EPIs would most effectively inhibit the efflux of different antibiotics by interaction with the switch loop.

Due to the complexity of these macromolecular structures progress on elucidating their assembly and structure was slow. Only very recently Du et al. (2014) used a creative approach of genetic fusion proteins to solve the first structure of a partially active, fully assembled, tripartite pump in the presence of a modulatory partner. This structure of AcrA–AcrB–AcrZ–TolC shed light on long disputed subunit stoichiometries and revealed that the complex assembles in a 3 : 6 : 3 ratio of AcrB : AcrA : TolC with one monomer of AcrZ bound to each subunit of AcrB. The role of the small protein AcrZ is not clear, however, as it alters the substrate specificity of AcrB (Hobbs et al., 2012) it most likely plays a modulatory role.

The structural similarity between transporters from different Gram-negative organisms means that EPIs developed against, e.g., the AcrA–AcrB–TolC efflux pump from E. coli would most likely be effective against other pathogens also. Our current understanding of the structure and function of RND efflux pumps from Gram-negative bacteria could therefore provide the basis for the informed and efficient design of inhibitors against these protein complexes.

Approaches to Inhibit Drug Efflux

The expression, function and assembly of drug efflux pumps of the RND class can be targeted in several ways (Figure 2).

Targeting the Regulatory Network that Controls the Expression of Efflux Pumps as Levels of Pump Expression are Controlled by Activators and Repressors

Some progress has already been made in understanding the regulation of efflux pump expression, e.g., expression of AcrB from Salmonella enterica (Blair et al., 2014) and the regulation of efflux pump expression in P. aeruginosa (Wilke et al., 2008; Starr et al., 2012; Hay et al., 2013; Purssell and Poole, 2013; Lau et al., 2014). The expression levels of efflux pumps could be measured by real time PCR or with green fluorescent protein reporter fusions (Bumann and Valdivia, 2007; Ricci et al., 2012). Both these methods are amenable to high-throughput processing.

Changing the Molecular Design of Old Antibiotics so that they are No Longer Recognized and Transported by the Efflux Pump

Given the wide range of compounds which could be recognized by drug efflux transporters, the plasticity in the binding sites, and the redundancy in aromatic residues in the binding pocket which could stabilize substrate binding (Du et al., 2013), this approach might prove a daunting task. In addition, altering the chemical structure of the antibiotic might render it less efficient against its intended cellular target. However, some progress has been made in this regard for a different class of drug efflux protein, the ATP binding cassette transporter, human P-glycoprotein where the substrate taxol was chemically modified so that P-glycoprotein no longer recognized it. This allowed the drug to cross the blood brain barrier and access its target receptor without being removed by P-glycoprotein (Rice et al., 2005).

Preventing the Assembly of the Efflux Pump Components into a Functional Tripartite Pump by Targeting Protein–Protein Interfaces

This is a very promising approach which is still under-developed due to the lack of information of how tripartite pumps assemble. However, Tikhonova et al. (2011) showed that designed ankyrin repeat proteins (DARPs) could inhibit AcrAB-TolC function by inhibiting the interaction between AcrA and AcrB. The recent structure of a complete tripartite drug efflux pump and the information gained from that also opens up exciting new possibilities (Du et al., 2014). The interaction of purified protein components of the pump with each other can be measured with surface plasmon resonance (SPR). The ability of efflux pumps to assemble in vivo can be measured by cross-linking in whole cells with subsequent co-purifying of the pump components (Welch et al., 2010).
Disrupting the Interaction Between AcrB and AcrZ

The exact role of AcrZ in drug efflux is still ill-defined. However, as AcrA–AcrB–TolC has a diminished ability to confer resistance to some drugs in the absence of AcrZ (Hobbs et al., 2012), this approach could be promising for restoring sensitivity to some antibiotics. Homologs of AcrZ are found in most Gram-negative bacteria, therefore the modulatory effect of RND class of transporters by small proteins is probably a widely conserved occurrence. The interaction between the IMP and a small protein such as AcrZ could be measured with SPR or with cross-linking in cells as mentioned above.

Directly Blocking the IMP with a High Affinity Competing Substrate or Trapping the IMP in an Inactive Conformation

The recent crystal structure of AcrB and MexB bound to an inhibitor (Nakashima et al., 2013) and the advances in our understanding of how drugs are bound makes this option very attractive (see Efflux Pump Inhibitors Against Gram-Negative Bacteria Identified So Far). The ability of compounds to inhibit antibiotic efflux can be measured using drug accumulation or drug efflux assays (see Inhibition of Substrate Transport), while direct interaction between the test compound and the IMP component could be determined with isothermal calorimetry (ITC) or SPR (Tikhonova et al., 2011).

Blocking the Exit Duct (the OMP)

A set of indole derivatives was designed based on the structure of TolC. These compounds were able to synergise with antibiotics and were reported to act on TolC specifically, presuming by preventing opening of the channel (Zeng et al., 2010). In addition, TolC from E. coli contains an electronegative entrance formed by an aspartate ring which is widely conserved throughout the TolC family and which could be a target for blocking by large cations (Andersen et al., 2002). The biggest challenge with this approach is achieving selectivity to the bacterial pores. Blocking of the OMP could be detected by inhibition of antibiotic efflux through the tripartite pump or by disruption of TolC-mediated conductance.

Depleting the IMP From the Energy Needed to Drive the Drug/H⁺ Antiport Reaction

The proton motive force (pmf) can easily be disrupted by the use of ionophores or compounds that disrupt the membrane integrity in one way or another. However, these effects are mostly not specific for bacterial membranes and hence compounds that act in this way would be cytotoxic to the host cells too. The magnitude of the pmf and the effect of test compounds on these could be determined by the use of fluorescent probes specific for the ΔΨ or ΔpH components of the pmf (Venter et al., 2003).

How Could EPIs be Identified?

Significant effort went into the biochemical and structural characterization of drug efflux proteins from Gram-negative bacteria. Recent successes such as the structural determination of an intact pump and of IMPs bound to an inhibitor (Nakashima et al., 2013; Du et al., 2014) offer a solid platform for the rational design of EPIs using quantitative structure-activity relationship data (Ruggerone et al., 2013a; Wong et al., 2014; Figure 3).

Recently we used in silico screening to identify compounds which would bind to AcrB with reasonable affinity. Of the roughly fifty compounds docked, six compounds were selected for further study. The docking allowed us to provide an order of efficiency of the compounds as potential EPIs. The biochemical data compared well with the predictions from the docking showing that in silico screening could be used as an effective screening tool to limit the amount of experiments needed or save on precious and hard earned purified natural products (Ohene-Agyei et al., 2014).

Another approach with good scope for success is investigating compounds purified from plants (Tegos et al., 2002). Traditional peoples have used plants to treat infections for 100s if not 1000s of years. In western medicine, plants are thus far an under-utilized source of chemical components in the treatment of infectious disease. Resistance to medicinal plant extracts have not been described yet and extracts of herbal medicines have been shown to potentiate antibiotic action in resistant pathogens (Garvey et al., 2011; Ohene-Agyei et al., 2014). Therefore, it is likely that as well as antibacterial chemicals, plants may also produce compounds that circumvent efflux-mediated resistance. Hence, activity guided fractionation can be used to identify the bio-active phytochemicals in plant extracts with EPI activity against Gram-negative organisms (Garvey et al., 2011).

Tools for Studying Efflux Pump Inhibitors

The most significant problem in current screening campaigns for EPIs is that in many cases the synergism observed could be attributed to non-specific damage to the bacterial membrane. This would be a strong indicator the compound would have similar activity against mammalian cells and hence would be cytotoxic. This was clearly the case for the EPI Phe-Arg-β-naphthylamide (PAβN; Marquez, 2005; Lomovskaya and Zgurskaya, 2011).

Therefore, there need to be a thorough investigation in order to verify true EPI action (Figure 3). Compounds that permeabilise the membrane of Gram-negative organisms will always show synergism with antibiotics. For example, the modulatory effect of α-tocopherol in multidrug resistant Gram-negative bacteria such as P. aeruginosa and E. coli could most probably be attributed to the effects of α-tocopherol on the membrane (Andrade et al., 2014). It is therefore important that potential inhibitors are not only identified on their synergism with antibiotics, but that a subsequent biochemical assays are performed to determine that the compounds are truly acting by inhibiting drug efflux.
In order to qualify as an EPI a compound must be able to satisfy the following criteria as stipulated by Lomovskaya et al. (2001).

(a) It must potentiate the activity of antibiotics to which a strain has developed resistance as a result of the expression of a drug efflux pump.
(b) It should not have an effect on sensitive strains which lack the drug efflux pump.
(c) It must not reduce the MIC of antibiotics which are not effluxed.
(d) It must increase the level of accumulation and decrease the level of extrusion of compounds which are substrates of the efflux pump.
(e) It must not permeabilise the outer membrane.
(f) It must not affect the proton gradient across the inner membrane.

All the above criteria can be addressed with well-developed techniques as outlined below and in Figure 3, which would be amenable to scale-down for high throughput analysis.

**Measuring Synergism**

The first thing to do is to determine the MIC of the test compound using standard broth dilution assays (Lomovskaya et al., 2001; Welch et al., 2010; Ohene-Agyei et al., 2012, 2014). Ideally the compound should not be toxic to bacterial cells or only toxic at high concentrations. This would prevent resistance against the test compound from developing very quickly. The compound would then be used at concentrations below its MIC (usually 4 times lower than the MIC) to test for synergism with antibiotics to which the organism has developed resistance. Synergism is best studied using checkerboard assays. These assays could be performed in a 96-well plate format with the antibiotic serially diluted along the ordinate and the test compound serially diluted along the abscissa (Lomovskaya et al., 2001; Orhan et al., 2005; Ohene-Agyei et al., 2014). The MIC of the antibiotic is determined in the presence of a range of different concentrations of the compound. Antibiotic-EPI interactions are subsequently classified on the basis of fractional inhibitory concentration (FIC). The FIC index is the sum of the FIC of each of the antibiotics, which in turn is defined as the MIC of the antibiotic when used in combination divided by the MIC of the antibiotic when used alone. The combination is considered synergistic when the $\Sigma$ FIC is ≤0.5, indifferent when the $\Sigma$ FIC is >0.5 to <2, and antagonistic when the $\Sigma$ FIC is ≥2.

**Ensuring the Compound has no Effect on Strains Which Lack the Drug Efflux Pump**

An effective way of testing the effect of a compound on efflux pump mediated resistance is to use a wild-type antimicrobial
resistant strain and a sensitive strain with a genomic deletion of the IMP. Checkerboard assays can be performed on the wild type strain to determine if MIC drop toward that of sensitive strain. Conversely the compound should not have an effect on the MIC of the sensitive strain.

However, it is important not to use a strain with a TolC deletion. TolC is a multi-functional protein that operates with the majority of MFP-dependent transporters encoded in the genome of E. coli (Zgurskaya et al., 2011). Results from TolC minus cells would therefore be complicated by effects which are not related to active drug efflux (Ohene-Agyei et al., 2014).

**Inhibition of Substrate Transport**

The ability of a potential EPI to inhibit substrate transport in a drug efflux pump can be measured by performing substrate accumulation assays or by measuring substrate efflux in the absence/presence of the putative EPI. Many fluorescent compounds are also substrates for drug efflux pumps. If these compounds undergo a change in fluorescence when bound to DNA/membrane lipids they can be used to measure the efflux activity of drug transporters. Many fluorescent compounds fulfill this role and are frequently used to measure drug efflux; examples are Hoechst 33342, berberine, ethidium bromide, TMA-DPH [1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene p-toluenesulfonate], N-phenylnaphtylamine and Nile Red which display enhanced fluorescence intensity when accumulated inside the cell or doxorubicin and rhodamine 6G for which accumulation inside cells results in quenching of the fluorescence signal (Lee et al., 2001; Lomovskaya et al., 2001; Seeger et al., 2008a,b; Ohene-Agyei et al., 2012, 2014; Cha et al., 2014). In drug accumulation assays the difference in rate of accumulation of the fluorescent compound between cells with and without an active efflux pump are used as an indication of efflux, since efflux will result in lower accumulation of compound. In drug efflux assays, the de-energized cells are pre-loaded with the fluorescent compound and then energized by the addition of glucose to catalyze drug efflux (observed as a drop in fluorescence). Drug influx assays are more straightforward and much quicker to perform than drug-efflux assays as de-energization and pre-loading can be time consuming. In addition, all the samples must be pre-loaded to the same level of fluorescence to avoid differences in efflux rate as a result of differences in the concentration of drug inside the cell. The main drawback of using fluorescent compounds to measure the effect of an EPI on drug efflux is that the potential EPI could be highly colored or fluorescent itself to measure the effect of an EPI on drug efflux is that the cell. The main drawback of using fluorescent compounds is dependent on the pmf as it catalysis substrate/H\(^{+}\) symport. Lomovskaya et al. (2001) probed the intracellular \(\beta\)-lactamase, hence nitrocefin hydrolysis can be followed directly by a simple fluorescence assay utilizing the fluorescent membrane potential probe 3,3′-diethyloxacarbocyanine iodide (DIOC2(3); Venter et al., 2003). Moreover, the DIOC2(3) assay can easily be adapted to 96-well format for the quick analysis of test compounds on the inner membrane in high-throughput screening.

**Use of a Non-Substrate**

Another way of ruling out false positives and establishing that compounds do not act non-specifically is to measure the effect of the test compound on an antibiotic which is not an efflux pump substrate. For example our group used rifampicin, which is not transported by the AcrAB-TolC drug efflux pump from E. coli (Ohene-Agyei et al., 2014). The test compounds should not lower the MIC of rifampicin. Any reduction in the MIC of rifampicin would indicate that the compound does not potentiate antibiotic action by inhibition of efflux, but acts by indirect means such as permeabilization of the membrane.

**EPIs Against Gram-Negative Bacteria Identified so Far**

The first EPI to be identified against RND pumps in Gram-negative bacteria was the peptidomimetic PAßN, originally referred to as MC-2077110. PAßN was identified in a screen for levofloxacin potentiators against resistant P. aeruginosa. Unfortunately, in addition to efflux pump inhibition it also...

**Testing of Outer Membrane Permeabilization**

The most effective method to measure outer membrane permeabilization is the nitrocefin hydrolysis method. Nitrocefin is a chromogenic \(\beta\)-lactam which changes from yellow (~380 nm) to red (~490 nm) when it is hydrolyzed by the periplasmic \(\beta\)-lactamase, hence nitrocefin hydrolysis can be followed by measuring the absorbance at 490 nm. If the test compound permeabilises the outer membrane, nitrocefin will diffuse more quickly over the membrane and hence the rate of nitrocefin hydrolysis will increase as a result (Lomovskaya et al., 2001; Ohene-Agyei et al., 2014). It is important to perform these essays in the presence of the ionophore CCCP to de-energize cells and prevent nitrocefin efflux.

**Testing of Inner Membrane Permeabilization**

Several methods exist to measure permeabilization of the inner-membrane. A DNA stain which does not penetrate the membrane of intact bacterial cells and which will undergo an increase in fluorescence quantum yield when bound to DNA such as propidium iodide or SYTOX Green could be used (Roth et al., 1997; Nakashima et al., 2011). SYTOX Green would be preferred for its sensitivity as it undergoes a >500-fold enhancement in fluorescence emission when bound to DNA.

Other methods to measure the intactness of the bacterial inner membrane involve the use or measurement of the pmf in E. coli. Opperman et al. (2014), employed an assay based on the uptake of \([\text{methyl-}\text{3H}]\beta\text{-D-thiogalactopyranoside ([3H]TMG)}\) by the LacY permease. The activity of the lactose permease is dependent on the pmf as it catalysis substrate/H\(^{+}\) symport. Lomovskaya et al. (2001) probed the intracellular \(\beta\)-lactamase, hence nitrocefin hydrolysis can be followed directly by a simple fluorescence assay utilizing the fluorescent membrane potential probe 3,3′-diethyloxacarbocyanine iodide (DIOC2(3); Venter et al., 2003). Moreover, the DIOC2(3) assay can easily be adapted to 96-well format for the quick analysis of test compounds on the inner membrane in high-throughput screening.
| Compound | Source | Protein/Organism | Actions $^1$ | Essays performed | Reference |
|----------|--------|-----------------|--------------|------------------|-----------|
| **Synthetic Compounds** | | | | | |
| Phe-Arg-β-naphthylamide (PAβN; MC-207,110) | Synthetic | MexAB-OprM, MexCD-OprJ, MexEF-OprN (Pseudomonas aeruginosa) | Synergise with fluoroquinolones | Antibacterial | Lomovskaya et al. (2001) |
| 7-nitro-8-methyl-4-[2’-(piperidino)ethyl]aminoquinoline | Alkylamino-quinolines | AcrAB-TolC (Enterobacter aerogenes) | Reduced MIC of Cam, Nor, and Tet; Increased Cam uptake | Antibacterial | Maflea et al. (2003) |
| 2,8-dimethyl-4-[2’-(pyrrolidinoethyl)]oxyquinoline | Alkoxy-quinoline derivative | E. aerogenes Klebsiella pneumonia | Reduced MIC of Nor, Tet, Cam | Antibacterial | Chevalier et al. (2004) |
| 1-(1-Naphthylmethyl)piperazine (NMP) | Synthetic | AcrAB, AcrEF (Escherichia coli) | Reduction in MICs of Lev, Oxa, Rif, Cam, Ciprofloxacin | Antibacterial | Kern et al. (2006) |
| New chloroquinoline derivatives | Fluoroquinolones | AcrAB-ToIC (E. aerogenes) | Reduced MIC of Cam | Antibacterial | Ghisalberti et al. (2006) |
| 3-amino-6-carboxylindole, 3-nitro-6-amino-indole | Designed and synthesized based on TolC structure | AcrAB-ToIC (E. coli) | Reduced MIC of cam, tet, ery, and cip | Antibacterial | Zeng et al. (2010) |
| 4-(3-morpholinopropylamino)quinazoline | 4-alkylaminoquinazoline derivatives | AcrAB-ToIC MexAB-OprM (E. coli P. aeruginosa) | Reduced MIC of Cam, Nal, Nor, and Spfx; Increased Cam uptake | Antibacterial | Mahamoud et al. (2011) |
| MBX2319 | Synthetic pyranopyridine | AcrB (E. coli) | Decreased MIC of Cip, Lev, and Prl | Synergism | Vargiu et al. (2014), Opperman et al. (2014) |
| 2-substituted benzothiazoles | Synthetic | AdeABC (Acinetobacter baumannii) | Reduced MIC of ciprofloxacin | Antibacterial | Yilmaz et al. (2014) |
| **Natural Compounds** | | | | | |
| EA-371α and EA-371δ | Streptomyces MF-EA-371-NS1 | MexAB-OprM (P. aeruginosa) | Reduced MIC of Lev | Synergism | Lee et al. (2001) |
| Geraniol | Helichrysum italicum | E. coli P. aeruginosa A. baumanii | Reduced MIC of β-lactams, quinolones, and Cam | Antibacterial | Lorenzi et al. (2009) |
| Plumbagin | Plumbago indica | AcrB (E. coli) | Reduced MIC of Ery, Cam, TET, SDS, Tet | Antibacterial | Ohene-Agyei et al. (2014) |
| Nordihydroguaretic acid (NDGA) | Creosote bush | AcrB (E. coli) | Reduced MIC of Ery, Cam, Nov, Tet, and TET | Antibacterial | Kurincic et al. (2012) |
| Shikonin | Lithospermum erythrorhizon | AcrB (E. coli) | Reduced MIC of TET | Antibacterial | Negi et al. (2014) |
| (-)-epigallocatechin gallate (EGCG) | Green tea | Campylobacter spp. | Reduced MIC to Ery and Carboxymycin | Antibacterial | Kurincic et al. (2012) |
| Curcumin | Curcuma longa (Zingiberaceae) | P. aeruginosa | Reduced MIC of Mem, Carb, Caz, Gen, and Cip | Antibacterial | Kurincic et al. (2012) |

(Continued)
TABLE 1 | Continued

| Compound                        | Source             | Protein/Organism          | Actions1                                      | Essays performed                  | Reference          |
|---------------------------------|--------------------|---------------------------|----------------------------------------------|-----------------------------------|--------------------|
| Lanatoside C and diadzein       | Phytochemical      | AcrB, MexB (E. col, P. aeruginosa) | Reduced MIC of Lev and Carb                  | High-throughput virtual screening | Aparna et al. (2014) |
|                                 |                    |                           | Increased accumulation of EtBr              | Synergism                         |                    |
| 4-hydroxy-α-tetralone           | Ammannia sp        | E. col                    | Reduced MIC of Tet                          | RT-PCR study                      | Dwivedi et al. (2014) |

Non-antibacterial drugs

| Compound                        | Source             | Protein/Organism          | Actions1                                      | Essays performed                  | Reference          |
|---------------------------------|--------------------|---------------------------|----------------------------------------------|-----------------------------------|--------------------|
| Trimeprin and Epinephrine       | Small heterocyclic or nitrogen-containing drugs | S. typhimurium E. cloace S. marcesens P. aeruginosa K. pneumoniae E. col | Reduced MIC of Cip                 | Antibacterial                     | Piddock et al. (2010) |
| Chlorpromazine, Amitryptiline, Trans-chlorprothixene | Non-antibiotic drugs | P. aeruginosa | Reduced MIC of Pen, Cxm, and Tob              | Antibacterial                     | Kristiansen et al. (2010) |
| Sertraline                      | Selective Serotonin Re-uptake Inhibitors | AcrAB, AcrEF, MctEF, and MexAB | Inhibition of Nile Red efflux                | Inhibition of efflux RT-PCR       | Bohnert et al. (2011) |
| Artesunate                      | Anti-malarial drug | AcrAB-ToIC (E. col)       | Reduced MIC of β-lactam antibiotic           | Antibacterial                     | Li et al. (2011)    |
|                                 |                    |                          | Increased Dau uptake                         | Synergism                         |                    |
|                                 |                    |                          | Reduce mRNA expression                       | Substrate accumulation RT-PCR     |                    |
| Pimozide                        | Neuroleptic drug   | AcrAB-ToIC (E. col)       | Reduced MICs of Oxa and EtBr                 | Synergism                         | Bohnert et al. (2013) |
|                                 |                    |                          | Inhibition of Nile rRed efflux               | Synergism                         |                    |

1 Abbreviations used: Cam, Chloramphenicol; Carb, Carbenicillin; Caz, Cefazidine; Cip, Ciprofloxacin; Clr, Clarithromycin; Cxm, Cefuroxime; Dau, Daunomycin; Ery, Erythromycin; EtBr, Ethidium Briomide; Gen, Gentamicin; Lev, Levofloxacin; Mem, Meropenem; Nal, Nalidixic acid; Nor, Norfloxacin; Oxa, Oxacin; Pen, Penicillin; Prf, Piperacillin; Rif, Rifampicin; Spfx, Sparfloxacin; Tet, Tetracycline; Tob, Tobramycin; TPP, Triphenylphosphonium.

permeabilized the outer membrane (Lomovskaya et al., 2001). Derivatives of PAβN with reduced toxicity, enhanced stability, and better solubility were developed and advanced to the pre-clinical stage, however, failed due to toxicity issues (Marquez, 2005; Lomovskaya et al., 2006; Lomovskaya and Zgurskaya, 2011; Bhardwaj and Mohanty, 2012).

The structural basis for the inhibition of the RND transporters has been recently described with the publication of the crystal structures of AcrB from E. coli and MexB from P. aeruginosa bound to a pyridopyrimidine derivative D13–D900 (Nakashima et al., 2013). The inhibitor binding almost overlapped with the binding of the substrates minocycline and doxorubicin, while part of the inhibitor inserted into a narrow phenylalanine rich region in the deep binding pocket, termed the hydrophobic trap by the authors. The authors suggested that the inhibitor competitively inhibit substrate binding and hinders the functional rotation of the efflux pumps.

As there is only one structure of a RND protein bound to an inhibitor published to date, docking, and molecular simulation studies were used to investigate the putative binding modes of other inhibitors such as PAβN and NMP (Vargiu et al., 2014) while in silico screening also provided information on the binding of putative EPIs (Ohene-Agyei et al., 2014). Both PAβN an NMP were predicted to interact with the switch loop while D13–D9001and MBX2319 have more interactions with the hydrophobic trap first identified by Nakashima et al. (2013).

Table 1 summarizes the compounds reported to act as EPIs against Gram-negative organisms so far. The term EPI is used loosely here as some of the included compounds were identified based on their synergism with one or more antibiotic while no further analysis was performed to study the mechanism of inhibition or rule out non-specific effects such as membrane permeabilization.

**Conclusion**

There are various papers reporting the ability of crude extracts from plants or other organisms to reduce antibiotic resistance that were not dealt with in this review. As can be seen from Table 1, there is also a sizable amount of pure compounds which were able to synergise with antibiotics against drug resistant Gram-negative bacteria. However, the translation of these promising compounds into EPIs for clinical application is still lacking. The most probable reason for the discrepancies in lead compounds and final outcome is the deficiency of follow through from first identification of a compound with synergistic effects to identification of true EPI activity and providing a thorough
inhibition into mechanism of action. With this review we aimed to summarize the current knowledge of how drug efflux can be inhibited.

The tools necessary to identify, test and characterize the mechanism of action of a putative EPI were also provided in order to aid the discovery and development of EPIs with which we would be able to stem the tide of multidrug resistant Gram-negative infections.

References

Amaral, L., Martins, A., Spengler, G., and Molinar, J. (2014). Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them. Front. Pharmacol. 4:168. doi: 10.3389/fphar.2013.00168

Andersen, C., Koronakis, E., Hughes, C., and Koronakis, V. (2002). An apportionate ring at the TolC tunnel entrance determines ion selectivity and presents a target for blocking by large cations. Mol. Microbiol. 44, 1131–1139. doi: 10.1046/j.1365-2958.2002.02988.x

Andrade, J. C., Morais-Braga, M. F., Guedes, G. M., Tintino, S. R., Freitas, M. A., Menezes, L. R., et al. (2014). Enhancement of the antibiotic activity of aminoglycosides by alpha-tocopherol and other cholesterol derivatives. Biomed. Pharmacother. 68, 1065–1069. doi: 10.1016/j.biopha.2014.10.011

Aparna, V., Dineshkumar, V., Mohanalakshmi, N., Velmurugan, D., and Hopper, W. (2014). Identification of natural compound inhibitors for multidrug efflux pumps of Escherichia coli and Pseudomonas aeruginosa using in silico high-throughput virtual screening and in vitro validation. PLoS ONE 9:e101840. doi: 10.1371/journal.pone.0101840

Bassetti, M., Merelli, M., Temperoni, C., and Astilean, A. (2013). New antibiotics for bad bugs: where are we? Ann. Clin. Microbiol. Antimicrob. 12, 22. doi: 10.1186/1476-0711-12-22

Baugh, S., Ekanayaka, A. S., Piddcock, L. J., and Webber, M. A. (2012). Loss of or inhibition of all multidrug resistance efflux pumps of Salmonella enterica serovar Typhimurium results in impaired ability to form a biofilm. J. Antimicrob. Chemother. 67, 2409–2417. doi: 10.1093/jac/dks228

Baugh, S., Phillips, C. R., Ekanayaka, A. S., Piddcock, L. J., and Webber, M. A. (2014). Inhibition of multidrug efflux as a strategy to prevent biofilm formation. J. Antimicrob. Chemother. 69, 673–681. doi: 10.1093/jac/dkt420

Bhardwaj, A. K., and Mohanty, P. (2012). Bacterial efflux pumps involved in multidrug resistance and their inhibitors: rejuvenating the antimicrobial chemotherapy. Recent Pat Antinfarmct Drug Discov. 7, 73–89. doi: 10.2174/157489111279982970

Blair, J. M., Smith, H. E., Ricci, V., Lawler, A. J., Thompson, L. J., and Piddock, R. J. (2014). Inhibition of efflux systems of Pseudomonas aeruginosa and Klebsiella pneumoniae strains. Antimicrob. Agents Chemother. 48, 1043–1046. doi: 10.1128/AAC.48.3.1043-1046.2004

Bumann, D., and Valdivia, R. H. (2007). Identification of host-induced pathogen genes by differential fluorescence induction reporter systems. Nat. Protoc. 2, 770–777. doi: 10.1038/nprot.2007.78

Bush, K., Courvalin, P., Dantas, G., Davies, J., Eisenstein, B., Huovinen, P., et al. (2011). Tackling antibiotic resistance. Nat. Rev. Microbiol. 9, 894–896. doi: 10.1038/nrmicro2693

Acknowledgments

Work in HV’s laboratory is funded by the University of South Australia, the Sansom Institute for Health Research and the Australian Research Council (Grant LE150100203 for screening of EPIs to HV). RM is the recipient of an Australian post-graduate award. HV and SM are co-recipients of a China–Australia Centre for Health Sciences Research Grant.

Butler, M. S., and Cooper, M. A. (2011). Antibiotics in the clinical pipeline in 2011. J. Antimicrob. Chemother. 64, 413–425. doi: 10.1093/jac/dja021

Cha, H. J., Muller, R. T., and Pos, K. M. (2014). Switch-loop flexibility affects transport of large drugs by the promiscuous AcrB multidrug efflux transporter. Antimicrob. Agents Chemother. 58, 4767–4772. doi: 10.1128/aac.02733-13

Chevalier, J., Bredin, J., Mahamoud, A., Mallea, M., Barbe, J., and Pages, J. M. (2004). Inhibitors of antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains. Antimicrob. Agents Chemother. 48, 1043–1046. doi: 10.1128/AAC.48.3.1043-1046.2004

Chuanchuen, R., Karklkhoff-Schweizer, R. R., and Schweizer, H. P. (2003). High-level triclosan resistance in Pseudomonas aeruginosa is solely a result of efflux. Antimicrob. Agents Chemother. 37, 124–127. doi: 10.1128/AAC.43.9-117.11. doi: 10.1128/anurev-biochem-051013-022855

Du, D., Venter, H., Pos, K. M., and Luisi, B. F. (2013). “The machinery and mechanism of multidrug efflux in gram-negative bacteria,” in Microbial Efflux Pumps: Current Research, Chap. 3, eds E. W. Yu, Q. Zhang, and M. H. Brown (Ames, IA: Caister Academic Press), 35–48.

Du, D., Wang, Z., James, N. R., Voss, J. E., Klimont, E., Ohene-Agyei, T., et al. (2014). Structure of the AcrAB-ToLC multidrug efflux pump. Nature 509, 512–515. doi: 10.1038/nature13205

Dwivedi, G. R., Upadhyay, H. C., Yadav, D. K., Singh, V., Srivastava, S. K., Khan, F., et al. (2014). 4-Hydroxy-alpha-tetralone and its derivative as drug resistance reversal agents in multidrug resistant Escherichia coli. Chem. Biol. Drug Des. 83, 482–492. doi: 10.1111/cbdd.12263

Eicher, T., Brandstatter, L., and Pos, K. M. (2009). Structural and functional aspects of the multidrug efflux pump AcrB. Biol. Chem. 390, 693–699. doi: 10.1515/bc.2009.090

Eicher, T., Cha, H. J., Seeger, M. A., Brandstatter, L., El-Delik, J., Bohnert, J. A., et al. (2012). Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop. Proc. Natl. Acad. Sci. USA. 109, 5687–5692. doi: 10.1073/pnas.1114944109

Guarve, M. I., Rahman, M. M., Gibbons, S., and Piddock, L. J. (2011). Medicinal plant extracts with efflux inhibitory activity against Gram-negative bacteria. Int. J. Antimicrob. Agents 37, 145–151. doi: 10.1016/j.ijantimicag.2010.05.027

Ghisalberti, D., Mahamoud, A., Chevalier, J., Baitiche, M., Martino, M., Pages, J. M., et al. (2006). Chloroquinolines block antibiotic efflux pumps in antibiotic-resistant Enterobacter aerogenes isolates. Int. J. Antimicrob. Agents 27, 565–569. doi: 10.1016/j.ijantimicag.2006.03.010

Hay, T., Fraud, S., Lau, C. H., Gilmore, C., and Poole, K. (2013). Antibiotic inducibility of the mexXY multidrug efflux operon of Pseudomonas aeruginosa: involvement of the MexZ anti-repressor ArmZ. PLoS ONE 8:e56858. doi: 10.1371/journal.pone.0056858

Hirakata, Y., Kondo, A., Hoshino, K., Yano, H., Araki, K., Hirotani, A., et al. (2009). Efflux pump inhibitors reduce the invasiveness of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 34, 334–346. doi: 10.1016/j.ijantimicag.2009.06.007

Hirakata, Y., Srikumar, R., Poole, K., Gotoh, N., Suematsu, T., Kohno, S., et al. (2002). Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J. Exp. Med. 196, 109–118. doi: 10.1084/jem.20020005

Hobbs, E. C., Yin, X., Paul, B. J., Astarita, J. L., and Storz, G. (2012). Conserved small protein associates with the multidrug efflux pump AcrB and differentially affects antibiotic resistance. Proc. Natl. Acad. Sci. U.S.A. 109, 16696–16701. doi: 10.1073/pnas.120093109
Ikonomidou, A., Tsakris, A., Kanellopoulou, M., Maniatis, A. N., and Pournaras, S. (2008). Effect of the proton motive force inhibitor carbonyl cyanide-m-chlorophenylhydrazine (CCCP) on Pseudomonas aeruginosa biofilm development. *Lett. Appl. Microbiol.* 47, 298–302. doi: 10.1111/j.1472-765X.2008.02430.x

Kern, W. Y., Steinkel, P., Schumacher, A., Schuster, S., von Baum, H., and Bohnert, J. A. (2006). Effect of 1-(naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of *Escherichia coli*. *J. Antimicrob. Chemother.* 57, 339–343. doi: 10.1093/jac/dki445

Krishnamoorthy, G., Tikhonova, E. B., and Zgurskaya, H. I. (2008). Fitting periplasmic membrane fusion proteins to inner membrane transporters: mutations that enable *Escherichia coli* AcrA to function with *Pseudomonas aeruginosa* MexB. *J. Bacteriol.* 190, 691–698 doi: 10.1128/JB.01276-07

Kristiansen, J. E., Thomsen, V. F., Martins, A., Viveiros, M., and Amaral, L. (2010). Non-antibiotics reverse resistance of bacteria to antibiotics. *In Vivo* 24, 751–754.

Kurincic, M., Klancnik, A., and Smole Mozina, S. (2012). Effects of efflux pump inhibitors on erythromycin, ciprofloxacin, and tetracycline resistance in *Campylobacter* spp. isolates. *Microb Drug Resist.* 18, 492–501. doi: 10.1089/mdr.2012.0017

Lau, C. H., Cranham, T., Gilmore, C., Mullen, E., and Poole, K. (2014). AmgRS-mediated envelope stress-inducible expression of the mexXY multidrug efflux operon of *Pseudomonas aeruginosa*. *Microbiol. Res.* 169, 121–135. doi: 10.1016/j.micres.2013.03.008

Lee, J., Li, X., Bao, Y., Wang, Y., and Paul, S. (2014). Identification and characterization of TriABC-OpmH, a triclosan efflux pump of *Pseudomonas aeruginosa*. *InVivo* 28, 46–65. doi: 10.1038/nrd2200

Lee, M. D., Galazzo, J. L., Bostian, K. A., and Warren, M. S., et al. (2011). *Efflux Pumps from Gram-negative Bacteria: From Structure and Function to Inhibition*. Norfolk, VA: Caister Academic press.

Lomovskaya, O., Zgurskaya, H. I., Totrov, M., and Waitkins, W. J. (2006). Waltzing *Frontiers in Microbiology* | www.frontiersin.org 10 April 2015 | Volume 6 | Article 377

Lomovskaya, O., and Zgurskaya, H. I. (2011). *Identification and characterization of TriABC-OpmH, a triclosan efflux pump of Pseudomonas aeruginosa* requiring two membrane fusion proteins. *J. Bacteriol.* 189, 7600–7609. doi: 10.1128/JB.00850-07

Misra, R., and Bavro, V. N. (2009). Assembly and transport mechanism of tripartite drug efflux systems. *Biochim. Biophys. Acta* 1794, 817–825. doi: 10.1016/j.bbapap.2009.02.017

Murakami, S. (2008). Multidrug efflux transporter, AcrB–the pumping mechanism. *Curr. Opin. Struct. Biol.* 18, 459–465. doi: 10.1016/j.sbi.2008.06.007

Nakashima, S., Nakashima, R., Yamashita, E., Matsumoto, T., and Yamaguchi, A. (2006). Crystal structures of a multidrug transporter reveal a functionality rotating mechanism. *Nature* 443, 173–179. doi: 10.1038/nature05076

Nakashima, R., Sakurai, K., Yamazaki, S., Hayashi, K., Nagata, C., Hoshino, K., et al. (2013). Structural basis for the inhibition of bacterial multidrug exporters. *Nature* 500, 102–106. doi: 10.1038/nature12300

Nakashima, R., Sakurai, K., Yamazaki, S., Nishino, K., and Yamaguchi, A. (2011). Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. *Nature* 480, 556–569. doi: 10.1038/nature10641

Neri, N., Prakash, P., Gupta, M. L., and Mohapatra, T. M. (2014). Possible role of curcumin as an efflux pump inhibitor in multi drug resistant clinical isolates of *Pseudomonas aeruginosa*. *J. Clin. Diag. Res. 8*, Dc04–Dc07. doi: 10.7860/jcdr/2014/8329.4965

Nikaido, H. (2011). Structure and mechanism of RND-type multidrug efflux pumps. *Adv. Enzymol. Relat. Areas Mol. Biol.* 77, 1–60. doi: 10.1002/9780470920541.ch1

Nikaido, H., and Pages, J. M. (2011). Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. *FEBS Microbiol. Rev.* 36, 340–363. doi: 10.1111/j.1574-6976.2011.00290.x

Ogene-Agyei, T., Lea, J. D., and Venter, H. (2012). Mutations in MexB that affect the efflux of antibiotics with cytoplasmic targets. *FEBS Microbiol. Lett.* 333, 20–27. doi: 10.1111/j.1574-6968.2012.02594.x

Ohene-Agyei, T., Mowla, R., Rahman, T., and Venter, H. (2014). Ptochymochens increase the antibacterial activity of antibiotics by acting on a drug efflux pump. *Microbiol. Res.* 3, 885–896. doi: 10.1016/j.micres.212

Opperman, T. J., Kwasy, S. M., Kim, H. S., Nguyen, S. T., Housewart, C., D’Souza, S., et al. (2014). Characterization of a novel pyranopyrazine inhibitor of the AcrB efflux pump of *Escherichia coli*. *Antimicrob. Agents Chemother.* 58, 722–733. doi: 10.1128/AAC.01866-13

Orhan, G., Bayram, A., Zer, Y., and Balci, I. (2005). Synergy tests by E test and checkerboard methods of antimicrobial combinations against *Brucella melitensis*. *J. Clin. Microbiol.* 43, 140–143. doi: 10.1128/JCM.43.1.140-143.2005

Phillips, J. L., and Gnanakaran, S. (2015). A data-driven approach to modeling the tripartite structure of multidrug resistance efflux pumps. *Proteins* 83, 46–65. doi: 10.1002/prot.24632

Piddock, L. J. (2006a). Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. *Clin. Microbiol. Rev.* 19, 382–402. doi: 10.1128/cmrr.19.2.382-402.2006

Piddock, L. J. (2006b). Multidrug-resistance efflux pumps? Not just for resistance. *Nat. Rev. Microbiol.* 4, 629–636. doi: 10.1038/nrmicro1464

Piddock, L. J. (2014). Understanding the basis of antibiotic resistance: a platform for drug discovery. *Microbiology* 160, 2366–2373. doi: 10.1099/mic.0.082412-0

Piddock, L. J., Garvey, M. I., Rahman, M. M., and Gibbons, S. (2010). Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram-negative bacteria. *J. Antimicrob. Chemother.* 65, 1215–1223. doi: 10.1093/jac/dkq797

Poole, K. (2004). Efflux-mediated multiresistance in Gram-negative bacteria. *Clin. Microbiol. Infect.* 10, 12–26. doi: 10.1111/j.1469-0691.2004.00763.x

Poole, K. (2005). Efflux-mediated antimicrobial resistance. *J. Antimicrob. Chemother.* 56, 20–51. doi: 10.1093/jac/dki171

Poole, K. (2011). *Pseudomonas aeruginosa*: resistance to the max. *Front. Microbiol.* 2:65. doi: 10.3389/fmicb.2011.00065
Pos, K. M. (2009). Drug transport mechanism of the AcrB efflux pump. *Biochim. Biophys. Acta* 1794, 782–793. doi: 10.1016/j.bbapap.2008.12.015

Pumbwe, L., Wareham, D., Aduse-Opoku, J., Brazier, J., and Wexler, H. (2007). Genetic analysis of mechanisms of multidrug resistance in a clinical isolate of *Bacteroides fragilis*. *Clin. Microbiol. Infect.* 13, 183–189. doi: 10.1111/j.1469-0691.2006.01620.x

Pursell, A., and Poole, K. (2013). Functional characterization of the MexB repressor of the mexCD-opr efflux multidrug efflux operon of *Pseudomonas aeruginosa*. *Microbiology* 159(Pt 10), 2058–2073. doi: 10.1099/mic.0.06928-0

Ramos, J. L., Duque, E., Gallegos, M.-T., Godoy, P., Ramos-González, M. I., Rojas, A., et al. (2002). Mechanisms of solvent tolerance: AcrB multifunctional efflux pump in *Escherichia coli*. *Front. Microbiol.* 2, 1295–1298. doi: 10.1126/science.1131542

Segura, A., Molina, L., Fillet, S., Krell, T., Bernal, P., Muñoz-Rojas, J., et al. (2012). Solvent tolerance in gram-negative bacteria. *Curr. Opin. Biotechnol.* 23, 415–421. doi: 10.1016/j.copbio.2011.11.015

Silver, S., and Phung, L. T. (1996). Bacterial heavy metal resistance: new surprises. *Ann. Rev. Microbiol.* 50, 753–789. doi: 10.1146/annurev.micro.50.1.753

Starr, L. M., Fruci, M., and Poole, K. (2012). Pentachlorophenol induction of the *Pseudomonas aeruginosa* mexAB-oprM efflux operon: involvement of repressors NaC and MexR and the antirepressor ArmR. *PLoS ONE* 7:e32684. doi: 10.1371/journal.pone.0032684

Tegos, G., Stermitz, F. R., Komkov, Y., and Lewis, K. (2002). Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials. *Antimicrob. Agents Chemother.* 46, 3133–3141. doi: 10.1128/AAC.46.10.3133-3141.2002

Walmsley, A. R., and Rosen, B. P. (2009). *Transport Mechanisms of Resistance to Drugs and Toxic Metals: Antimicrobial Drug Resistance*. Berlin: Springer.

Welch, A., Ahaw, C. U., Jing, S., van Veen, H. W., and Venter, H. (2010). Promiscuous partnering and independent activity of MexB, the multidrug transporter protein from *Pseudomonas aeruginosa*. *Biochem. J.* 430, 355–364. doi: 10.1042/BJ20091860

WHO. (2014). *Antimicrobial Resistance: Global Report on Surveillance 2014*. Available at: www.who.int/drugresistance/documents/surveillancerapport/en/

Zgurskaya, H. I., Krishnamoorthy, G., Ntreh, A., and Lu, S. (2011). Mechanism and target validation of indole derivatives as inhibitors of the AcrAB-TolC multidrug efflux pump. *Biochem. J.* 438, 9–16. doi: 10.1042/BJ20111002

Zeng, B., Wang, H., Zou, L., Zhang, A., Yang, X., and Guan, Z. (2010). Evaluation of a series of 2-substituted benzothiazoles as AdeABC efflux pump inhibitors in *A. baumannii*. *J. Med. Chem.* 53, 1295–1301. doi: 10.1021/jm100897v

Zhang, Q., Lambert, G., Liao, D., Kim, H., Robin, K., Tung, C. K., et al. (2011). Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments. *Science* 333, 1764–1767. doi: 10.1126/science.1208747

Zgurskaya, H. I., Krishnamoorthy, G., Ntreh, A., and Lu, S. (2011). Mechanism and function of the outer membrane channel tolC in multidrug resistance and physiology of enterobacteria. *Front. Microbiol.* 2:189. doi: 10.3389/fmicb.2011.00189

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.